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ABSTRACT 
Background: We aimed to analyse clinical and gene expression profiles to predict 
pathologic complete response and disease-free survival using two consecutive, 
prospective, preoperative chemotherapy trial cohorts. 
Methods: Clinicopathological and gene expression data were evaluated in a cohort from 
two consecutive phase II preoperative studies that included patients with stage IIA–IIIC 
breast cancer of all subtypes. Analysed specimens were obtained before preoperative 
chemotherapy, and cDNA microarray analyses were performed using the Affymetrix 
Gene Chip U133 plus 2.0. 
Results: Between December 2005 and December 2010, 122 patients were analysed. The 
pathologic complete response rate was significantly higher in HER2+ and HR−/HER2− 
cancers. Age, pathologic complete response, HR−/HER2− status, and lymph node 
positivity (≽4) were significant poor prognostic factors for disease-free survival. For the 
cDNA microarray analyses, sufficient tumour samples were available from 78 of the 
107 patients (73%). An 8-gene signature predictive of pathologic complete response 
and a 17-gene signature predictive of prognosis were identified. Patients were 
categorised into low-risk (n = 45) and high-risk groups (n = 33) (HR 70.0, P = 0.004). 
Conclusions: This study yielded preliminary data on the expression of specific genes 
predicting pathologic complete response and disease-free survival in a cohort of 
chemonaı¨ve breast cancer patients. Further validation may distinguish those who would 
benefit most from perioperative chemotherapy as well as those needing further 
intervention. 
 
MANUSCRIPT 
Breast cancer is the most common cancer in women worldwide. Today, the majority of 
patients with operable breast cancer are offered systemic therapy to reduce the risk of 
distant recurrence. Preoperative chemotherapy reduces the tumour burden of operable 
and locally advanced breast tumours (clinical stage IIIB–C) and thereby improves 
resectability, with the same survival effect as postoperative chemotherapy (van der 
Hage et al, 2001; Wolmark et al, 2001; Rastogi et al, 2008; de Azambuja et al, 2014). In 
addition, preoperative treatment serves as an in vivo chemosensitivity test, allowing for 
early evaluation of the efficacy of chemotherapy (Schott and Hayes, 2012). 
Clinical response rates to preoperative chemotherapy range from 60 to 80%, 
whereas pathologic complete response (pCR) rates are B10–20% (Fisher et al, 1998; 
Smith et al, 2002), although both differ among tumour subtypes. According to a 
previous report, the pCR rates for hormone receptor-positive (HR+)/human epidermal 
growth factor receptor 2-negative (HER2-), HR+/human epidermal growth factor 
receptor 2-positive (HER2+), hormone receptor-negative (HR-)/HER2+, and 
HR-/HER2- subtypes were 13%, 19%, 48%, and 29%, respectively (Iwata et al, 2011). 
Patients who achieve pCR have a better prognosis compared with those who do not (van 
der Hage et al, 2001; Wolmark et al, 2001; Rastogi et al, 2008). Studies investigating 
the factors associated with tumour response to chemotherapy have shown that markers 
of tumour cell proliferation, including Ki-67 staining, histologic grade, negative 
oestrogen receptor (ER) status, and HER2 overexpression, are significantly associated 
with the pCR rate (Petit et al, 2004; Dowsett et al, 2006; Andre et al, 2008; Nishimura 
et al, 2010). However, these results come with some degree of controversy and little 
indication of their clinically applicable predictive value (Burcombe et al, 2005). The 
biological mechanisms that influence tumour responsiveness in the preoperative setting, 
including tumour recurrence, are not clearly understood. 
Gene expression profiling studies in human tumours have provided new 
insights into the genes and pathways that contribute to tumourigenesis and the gene 
expression signatures that are prognostic of patient outcome. Previous studies aimed at 
discovering genes associated with breast cancer recurrence have uncovered several 
genes associated with cellular proliferation, resulting in the identification of genes 
associated with poor patient prognosis (Huang et al, 2003; Dai et al, 2005). These gene 
expression data have the potential to aid the determination of accurate, individualised 
prognosis, for example, through Agendia’s MammaPrint and Genomic Health’s 21-gene 
Oncotype Dx systems (van ’t Veer et al, 2002; Paik et al, 2004; Paik et al, 2006). 
However, these approaches are based on node-negative, HR-positive early breast 
cancers, and no studies thus far have clearly identified gene signatures predicting both 
pCR and disease-free survival (DFS) from one cohort. 
Here, we aimed to analyse the clinicopathological and gene expression profiles 
to predict pCR and DFS in early breast cancers managed by preoperative chemotherapy, 
using data from longterm follow-up of two prospective studies. 
 
MATERIALS AND METHODS 
Patients and samples. We synthetically analysed the data of patients from our two 
previous consecutive prospective phase II studies in the preoperative chemotherapy 
setting, ‘Trial A’ (Tamura et al, 2011) and ‘Trial B’ (Ando et al, 2014). The two 
studies included patients with HER2+ and/or HER2-, and HR+ and/or HR- tumours. 
The trials had similar eligibility criteria; in brief, patients had histologically confirmed, 
previously untreated, unilateral, non-inflammatory invasive breast cancer. Histologic 
confirmation of invasive cancer was performed by core needle biopsy, and HER2- 
disease was assigned a score of 0 or 1+ based on immunohistochemistry or HER2 gene 
copy number: a chromosome 17 ratio of o2.0 by fluorescence in situ hybridisation 
(Wolff et al, 2007). Patients had clinical stage IIA–IIIC primary measurable disease. 
Other requirements included age ≽18 years, Eastern Cooperative Oncology Group 
(ECOG) performance status (PS) score of 0–1, and adequate organ function (white 
blood cell count ≽4000/ml, platelet count ≽100 000/ml, haemoglobin concentration ≽
9.0 g dl
-1
, serum bilirubin p2.0 mg dl
-1
, aspartate aminotransferase and alanine 
aminotransferase p100 IU l
-1
, serum creatinine ≼institutional upper limit of normal 
range, PaO2 ≽60mmHg, and baseline left ventricular ejection fraction >50%). 
Patients received 5-fluorouracil/epirubicin/cyclophosphamide (500/100/500 
mg/m
2
) q3w x 4 cycles, followed by paclitaxel (PTX) (80 mg/m
2
) q1w x 12 cycles or 
docetaxel (75 mg/m
2
) q3w x 4 cycles or, if HER2+, PTX/trastuzumab (loading dose 
4mg/kg, maintenance dose 2mg/kg) q1w x 12 cycles. 
This study was conducted according to a protocol approved by the institutional 
review board and independent ethics committee, and informed consent was obtained 
from all patients for the use of biopsy specimens and the analysis of clinical 
information. 
Clinical statistical analysis. Complete response rate was defined as no invasive 
residual tumour in breast and nodes, with noninvasive breast residuals allowed (ypT0/is, 
ypN0), a definition commonly used by MD Anderson Cancer Center, the Austrian 
Breast and Colorectal Cancer Study Group, and the Neo-Breast International Group 
(Green et al, 2005). Disease-free survival was estimated from the date of induction of 
adjuvant chemotherapy to the date of relapse or death from any cause (only relapses 
were considered events) using the Kaplan–Meier method. Potential predictive factors 
for pCR and recurrence were recorded, including patient age (≽35 vs <35 years), tumour 
stage (IIa–IIB vs IIIA–IIIC), subtype (HR+/HER2- vs HR+/HER2+, HR-/HER2+, and 
HR-/HER2-), nuclear grade (1 vs 2–3), pCR rate (pCR vs non-pCR), and lymph node 
involvement. Nuclear grade, pCR, and lymph nodes were diagnosed with surgical 
specimens by two pathologists. A logistic regression model was used to estimate the 
odds ratio comparing the odds of pCR. Cox proportional hazards regression was used to 
investigate the prognostic factors for DFS. 
Microarray process and statistical analysis. The mRNA was extracted from 
fine-needle biopsy samples performed at diagnosis before preoperative chemotherapy. 
cDNA was constructed from the mRNA of the breast cancer tissues by standard RT 
procedures. The probes were prepared by immunofluorescence labelling with cDNA 
and hybridised to chip arrays containing 54K probe sets (Affymetrix U133 plus 2.0). 
The data were processed by the robust multiarray average algorithm (Irizarry et al, 
2003; Gautier et al, 2004) using GeneSpring ver. 12.6 (Agilent Technologies, Santa 
Clara, CA, USA). These processed values were corrected for batch effects using the 
ComBat function in the R package sva (Leek et al, 2012). Institution, age, stage, 
menopausal status, subtype, grade, ductal carcinoma in situ, pCR, and event DFS were 
used as covariates to correct for batch effects. 
To identify a genomic signature of DFS using the data set after preprocessing, 
the 54 613 probes were filtered down to 104 probes, which satisfied the P-values of 
both the univariate Cox regression analysis and the significance analysis of microarrays 
(SAM) (Tusher et al, 2001) tests, which were o0.01. For the 104 probes, an iterative 
backward elimination feature selection procedure was applied using three-component 
partial Cox regression analysis (Li and Gui, 2004), where the partial Cox coefficients of 
the proteins were used for ranking (Ahdesmaki et al, 2013). During each iteration, the 
lowest ranking proteins were discarded after calculating the C-index (Harrell and Frank, 
2010), and this was continued until the two probes remained. The C-index was 
calculated for each number of probes sets (i.e., from 104 to 2 of the length). In this 
study, we determined the length with highest C-index as the optimal one of the genomic 
signature. 
Next, we developed the final genomic signature including these probes based 
on the partial Cox regression analysis. The DFS event risk based on the developed 
signature was quantified by the risk score that is defined as the linear combination of the 
signature probe values multiplied by their corresponding partial Cox model coefficients, 
first subtracted by the mean values of their probes. That is, the risk score for patient can 
(value of probe j - mean value of probe j in 78pts) βj, be written as Risk score = 
where L is the number of optima length andβj is the coefficient of the partial Cox 
regression model for probe j. The risk scores have by definition a sample mean of zero, 
and indicate high risk of DFS events for the larger value. 
Finally, we calculate the internal accuracy of the final genomic signature. The 
survival curves for DFS between the two groups of the patients with ≽0 of risk score 
and patients with <0 were compared by the Kaplan–Meier method and log-rank test. 
The hazard ratio and its 95% confidence interval for the risk score dichotomised by zero 
were also estimated by the ordinary Cox regression analysis. 
Additionally, we also identified the genes that were strongly correlated with 
pCR. Similar to the analyses for DFS, the 54 613 probes were filtered down to 363 
probes that satisfied the P-values of both the univariate logistic regression analysis and 
the SAM tests, which were o0.001. For the 363 probes, an iterative backward 
elimination feature selection procedure was applied using the ridge regression analysis 
(Friedman et al, 2010). Based on the area under the receiver operating characteristic 
curve (AUC), we determined the probes with highest AUC as the strongly correlated 
gene set. 
All statistical tests were two sided. These analyses were performed using the 
SAS software (version 9.3; SAS Institute Inc, Cary, NC, USA) and the original R codes. 
Average-linkage hierarchical clustering of genes and arrays was performed. We 
also conducted the clustering analysis using probes significant to the following gene 
groups: A, cell cycle regulator; B, signal; C, Rho family-related protein; D, blank; E, 
angiogenesisrelated protein; F, growth factor; G, cytokine; H, apoptosis factors; I, DNA 
transcription factors/damage response, repair, and combination; J,  
metabolism/translation/protein turnover; K, detoxification enzyme; L, 
transporters/nucleocytoplasmic transporters/ symporters and antiporters; M, cytoskeletal 
proteins; N, hormone-related and receptors; antibody-dependent cell-mediated 
cytotoxicity (ADCC), ADCC activators; Y, glyceraldehyde-3- phosphate 
dehydrogenase as a positive control. 
Apart from the above-mentioned analysis, we re-identified the probes that 
correlated with pCR. To this end, we used the cohort from Trial A as a training set, and 
the cohort from Trial B as a validation set. Similar to the above-mentioned analysis, we 
first filtered the probes using the x
2
 test to remove probe sets that did not display 
significant variation in expression across arrays concerning pCR, a method used by the 
Cancer and Leukaemia Group B study for acute myeloid leukaemia (Marcucci et al, 
2008). As the results, a total of ~8700 probes met the filtering criteria and were included 
in the next step, where Wilcoxon’s P-values by univariate and permutation tests were 
applied. The top-ranked probes were verified using the validation set based on the 
support vector machine with a linear kernel (Furey et al, 2000). The number of genes 
used in the formula was determined by a fivefold cross-validation. The HER2 status 
was also included in the formula. 
 
RESULTS 
Clinicopathological features predictive of pCR and DFS. Between July 2007 and 
December 2010, 122 patients were enrolled in the two consecutive prospective studies. 
Of these patients, 107 underwent long-term follow-up study. The median follow-up 
time from the start of preoperative chemotherapy was 64.1 months (range 14.3–106 
months). Table 1 summarises the patient characteristics. The median age was 51 (23–
75) years. The respective numbers of patients with ECOG PS of 0 and 1 were 115 and 
7; with tumour stages IIA, IIB, IIIA, IIIB, and IIIC were 30, 57, 20, 14, and 1; and with 
tumour status HR+/HER2-, HR+/HER2+, HR-/HER2+, and HR-/HER2- were 51, 18, 
29, and 24. The characteristics and results of the 107 patients were comparable to those 
of the original cohort (122 patients). The pCR rate of the 107 patients was 28% 
(HR+/HER2- : HR+/HER2+ : HR-/HER2+ : HR-/HER2- = 2.1% : 38% : 70% : 35%). 
Table 2A depicts the multivariate analysis with clinicopathological characteristics of 
predictive factors for pCR. The pCR rate was significantly higher in HR+/HER2+, 
HR-/HER2+, and HR-/HER2- breast cancers compared with HR+/HER2- cancers 
(P=0.004, P<0.001, and P=0.007, respectively). The 5-year DFS for all subtypes was 
77.4%. The survival curves for each subtype are shown in Figure 1. The HR-/HER2- 
subtype had a significantly poor prognosis (P=0.0045). Multivariate analysis revealed 
that non-pCR, age <35 years, HR-/HER2- subtype, and axillary lymph nodes ≽4 were 
significant poor prognostic factors (P=0.03, P=0.005, P<0.001, and P<0.001, 
respectively), as shown in Table 2B.  
 
 
  
  
 
 
Figure 1. Kaplan–Meier disease-free survival curves of patients stratified by subtype (n=107). The 
median follow-up time was 64 months. The 5-year DFS% (95% confidence interval (CI)) were as 
follows: HR+/HER2-, 79.9% (64.8, 89.0); HR+/HER2+, 83.1% (47.2, 95.5); HR-/HER2+, 86.7% 
(64.3, 95.5); and HR-/HER2-, 56.5% (34.3, 73.8). 
 
Microarray analysis. Primary breast cancer tissues were obtained from the 107 
patients by fine-needle biopsy; 78 (73%) samples contained sufficient mRNA for cDNA 
microarray analysis. Results of the gene signature analysis identified an 8-gene 
expression profile predictive of pCR and a 17-gene expression profile most associated 
with DFS, as shown in Table 3A and B. With the DFS 17-gene signature, which 
includes the apoptosis-related cysteine peptidase caspase-8 encoding gene (CASP8), 
patients were classified into a low-risk group (n=45) and a high-risk group (n=33) 
according to the risk score determined by the partial Cox regression model (Figure 2). A 
Cox proportional hazards regression to investigate the prognostic factors, including the 
gene expression profiles of low- and high-risk factors, for DFS showed that the gene 
profiling was the strongest factor (Table 4). 
Based on gene clustering analysis, the breast cancers were classified according 
to the following immunohistochemistry subtypes: luminal A and B, HER2-enriched, 
and triple-negative breast cancer (TNBC). Triple-negative breast cancer was further 
divided into two clusters most likely indicating basal-like and claudin-low intrinsic 
subtypes, as previously reported by Sorlie et al (2001), indicating the high quality of the 
representative method (Supplementary Data and Figure 1). The genes used in the 
clustering analysis is shown in Supplementary Table 1. When the clustering analysis 
using significant gene groups of A to N and Y was performed according to HER2 status, 
HER2+ breast cancers were successfully clustered using the B group gene probes, 
whereas HER2- breast cancers were clustered appropriately with the gene probes of the 
N, J, I, and H groups (data not shown). 
 In addition, using the training set, we identified the top-ranked gene probes 
associated with pCR (Wilcoxon’s P-value <0.01). On the basis of the 100 top-ranked 
genes (Supplementary Table 2), the training set was also used for model selection and 
resulted in the creation of a gene model for the HER2- breast cancers (HR+/ 
HER2- and HR-/HER2-) (Supplementary Figure 2). This analysis included 49 samples, 
which included 35 from the training set and 14 from the validation set. The 
discrimination markers predicting pCR were analysed using the training and validation 
sets, and the lowest test error of 7% was observed when the number of markers fitted in 
the model was four; these included HER2- status and the following three genes: 
promyelocytic leukaemia protein (PML), tryptophanyl-tRNA synthetase (TrpRS), and 
choline kinase alpha (CHKA) (Supplementary Figure 3). A similar analysis including 
the HER2+ subset failed to show a well-fitted model. 
 
 DISCUSSION 
Breast cancer is heterogeneous in terms of prognosis and response to chemotherapy, 
even among known intrinsic subtypes. Results from our clinicopathological data 
revealed that HER2þ and HR-/HER2- subtypes were predictive of pCR. A significantly 
poor DFS was observed in the HR-/HER2- subtype and in lymph node-positive tumours. 
These results are comparable with results previously reported such as a study by Liedtke 
et al (2008); therefore, our cohort of two combined trials is representative of the general 
cancer population. Liedtke et al (2008) found that the TNBC subtype had a higher pCR 
rate than the non-TNBC subtype, but a significantly decreased survival. This was 
explained by the heterogeneity of the TNBC subtype, as some patients achieved pCR 
with a good prognosis, whereas the majority did not achieve pCR and had a 
significantly worse prognosis than other subtypes. Lehmann et al (2011) proposed that 
TNBC could be classified into seven molecular subtypes, among which the pCR rate 
differed, as shown by Masuda et al (2013). These data, together with our own, suggest 
heterogeneity even among the known breast cancer subtypes. The finding that four or 
more positive axillary lymph nodes constituted a poor prognostic factor correlates with 
historical data showing that lymph node positivity is the most established and reliable 
prognostic factor for subsequent metastatic disease and survival (Fisher et al, 1993). 
 The microarray analysis that included the cohorts from two prospective 
preoperative studies yielded preliminary data showing that an 8-gene signature 
predicted pCR and a 17-gene signature predicted DFS. With the 17-gene signature we 
were able to discriminate low- and high-risk patients with a high hazard ratio of 70, 
showing a higher discriminating value than single clinical variables (e.g., histologic 
grade, HR status, HER2 status). Many studies have aimed to identify gene profiles 
predicting response and prognosis, including commercially available panels (van’t Veer 
et al, 2002; Paik et al, 2004; Paik et al, 2006; Nishio et al, 2014). Most are based on 
node-negative early breast cancers, and include only HR- or HR+ cancers. This study 
combined all subtypes, and identified two sets of gene clusters that, respectively, 
predicted pCR and PFS. By including all subtypes in the analysis, we tried to seek for a 
molecular feature that explains the difference in chemosensitivity and prognosis beyond 
the known biomarkers. There is more hidden biology than the already defined subtypes 
using HER2 and hormone receptor proteins, as the prognosis differs even among the 
same subtypes (Liedtke et al, 2008). Also, discordance of subtype between primary and 
metastatic sites have been reported (Falck et al, 2013; Yao et al, 2014), which also 
implies that the cancer is driven beyond the known biomarkers. Most molecular analysis 
in the literature are carried out in breast cancers of a certain HER2 or HR status and 
therefore our analysis is novel in that the identified signatures may be useful regardless 
of subtype and those with discordances or changes of subtype at metastatic sites or at 
relapse.  
 The 8-gene signature may identify which patients will benefit most from 
preoperative chemotherapy and which should initially undergo surgery. With the DFS 
prediction signature, we may be able to predict those who will benefit from additional 
adjuvant chemotherapy or extended hormone therapy. 
  The genes that were chosen in our two signatures did not show an overlap 
with genes in other microarray studies, namely those assessed with the MammaPrint 
(Agendia, Irvine, CA, USA) and Oncotype DX (Genomic Health, Redwood City, CA, 
USA) panels. Possible explanations are that our study included all subtypes regardless 
of node status, as well as patients who were treated or not treated with trastuzumab. 
Nonetheless, we identified a gene signature with a high prognostic power, assuming that 
molecular pathways other than the already known molecular subtypes are associated 
with tumour recurrence. Further, in our study the gene signature predicting pCR and 
DFS did not identify any overlapping genes between the two signatures. This result is 
supported by our clinicopathological data sets, where a discordance between pCR and 
DFS also occurred among subtypes. The HR-/HER2- subtype was associated with a 
significantly poor DFS compared with other subtypes, despite a relatively high pCR rate, 
which was also shown by Liedtke et al (2008). The NeoALTTO trial showed that dual 
anti-HER2 inhibition significantly increased pCR rate compared with trastuzumab alone, 
but at the same time did not show a survival difference between treatment groups (de 
Azambuja et al, 2014). A recent meta-analysis concluded that the pCR rate should not 
be used as a surrogate marker for survival (Cortazar et al, 2014). Therefore, response to 
chemotherapy and prognosis outcome may be a result from different biology. Using the 
two different signatures for analysis of tumour response to preoperative chemotherapy 
and its prognosis may provide a new means of making individual therapeutic decisions. 
Further, discordance of genomic signatures among studies is a well-discussed 
topic, and it is known that independent signatures may be similar in terms of outcome 
predictions despite a lack of gene overlap. Our Supplementary Data analysis in the 
HER2- subtype, resulting in a 3-gene signature, also did not show an overlap with the 8- 
or 17-gene signature. One explanation is that the number of samples used were different 
(49 vs 78). Also, two different analysis methods were used. The results of the 
Supplementary Data used a svm with linear kernel, which mainly focuses on the error 
rate, rather than the odds ratio. 
Our 8-gene signature predicting pCR included genes associated with 
tumourigenesis such as ADAM metallopeptidase domain 17 (ADAM17), glutaminase-2 
(GLS2), and HOXA6. The ADAM17 protein catalyses the release and activation of 
ligands such as transforming growth factor-a, which is essential in activating epidermal 
growth factor receptor (Blobel, 2005), and high expression of ADAM17 was associated 
with shorter survival in breast cancers (McGowan et al, 2008). Recently, in vitro data 
suggested that an antibody against ADAM17 had antitumour effects in TNBC cells 
(Caiazza et al, 2015). Glutaminase is involved in the Warburg effect in cancer cells, and 
two human glutaminase genes, GLS1 and GLS2, have been identified (Erickson and 
Cerione, 2010). A discovery of an alkyl benzoquinones that preferentially inhibit GLS2 
and subsequently reduces carcinoma cell proliferation and induced autophagy via 
AMPK-mediated mTORC1 inhibition has been reported (Lee et al, 2014). It suggested 
that the inhibition of GLS2 may be a potential anticancer target. HOX genes encode a 
highly conserved family of homeodomain-containing transcription factors that have 
crucial roles in determining the identity of cells and tissues during embryogenesis. 
Aberrant HOX gene expression has been linked to a variety of adult malignancies (Shah 
and Sukumar, 2010). In a study to analyse the expression of 39 HOX genes in malignant 
breast tissues, HOXA6 showed low expression levels along with HOXB8 and HOXC5 
in malignant tissues, whereas the other HOX family genes were expressed at higher 
levels (Hur et al, 2014). Our 17-gene signature that predicted DFS included CASP8, an 
apoptosis-related cysteine peptidase encoding gene. Caspase-8 has a central role in the 
transmission of the death signal in the death receptor (extrinsic) pathway of apoptosis 
by coupling the stimulation of death receptors to the activation of intracellular 
signalling cascades that eventually lead to cell death (Barnhart et al, 2003). It is 
frequently inactivated in tumours of breast, colon, or lung (Shivapurkar et al, 2002). 
Therapeutic agents such as interferon-γ and peptides induce caspase pathways, and 
microtubule-stabilising agents such as taxanes promote CASP8- mediated apoptosis, 
possibly via upregulation of components of the tumour necrosis factor-related 
apoptosis-inducing ligand pathway (Nimmanapalli et al, 2001; Muhlethaler-Mottet et al, 
2004) or by amplification of CASP8 activation via microtubule-anchored death effector 
domain ‘filaments’ (Mielgo et al, 2009). Based on these data, we assume that patients 
classified into the high-risk group by our 17-gene signature may benefit from more 
intensive chemotherapy, and those in the low-risk group may be able to avoid extra 
chemotherapy. 
As for the Supplementary Data, analysis using the training and validation sets 
identified HER2- status as well as three genes, namely PML, TrpRS, and CHKA, as the 
most accurate markers for predicting pCR. PML is a tumour suppressor gene as its 
expression is lost in several types of human cancers and is associated with tumour grade 
and progression (Gurrieri et al, 2004). TrpRS has been documented to function in 
proangiogenic responses (Wakasugi and Schimmel, 1999; Mirando et al, 2014). Human 
TrpRS exists in two forms: full-length protein and truncated TrpRS. The expression of 
mini TrpRS is stimulated by the antitumorigenic IGN-g (Rubin et al, 1991), and in a 
protein signature analysis with TNBC, TrpRS was identified as a good prognostic 
marker (Campone et al, 2015). CHKA catalyses the phosphorylation of choline and has 
been shown to be upregulated in many cancer types, including breast, lung, colorectral, 
and prostate cancer(Katz-Brull et al, 2002). When the gene is amplified, it modulates 
ER-driven proliferation and ER/oestrogen response element transactivation 
(Lopez-Knowles et al, 2015). With this three-gene model, validation set was used for 
performance evaluation, which resulted in a 93% accuracy rate on validation. The 
clustering analysis revealed that the HER2þ cancers correlated with only the B group 
gene probes, whereas the HER2- cancers showed a correlation with the N, J, I, and H 
groups. According to a pooled analysis of studies of gene modules and response to 
preoperative chemotherapy (Ignatiadis et al, 2012), high module scores for 
chromosomal instability, phosphatase and tensin homolog loss, and E2F3 transcription 
factor were associated with increased pCR probability in HER2- tumours. These 
findings, along with our current results, suggest that HER2- cancers possess marked 
heterogeneity, with many different processes and pathways associated with tumour 
growth or sensitivity to chemotherapy. This is in contrast to HER2+ cancers, in which 
HER2 amplification-driven oncogenesis has a much more significant role than other 
pathways. Therefore, we believe that using the proper sets of genes, pCR could be more 
successfully predicted in HER2- cancers compared with those that are HER2+, would 
be most successful in predicting pCR with the proper sets of genes. 
Some limitations of our analysis must be mentioned. First, the relatively small 
sample size may have increased the false discoverypositive rate. Second, all patients in 
the analysis received anthracycline plus taxane-based preoperative chemotherapy 
regimens. It is therefore not known if the associations between significant genes and 
pCR or DFS are anthracycline-specific or taxane-specific, or instead indicate general 
chemosensitivity. Third, validation of the gene signatures was not performed owing to 
the lack of events, which will be conducted in the future. Fourth, our analysis integrated 
all subtypes, which is also the novelty of our analysis, but identifying a predictive gene 
signature for each subtype may have been more suitable for clinical use. However, if 
analysis was carried out for each subtype, the number of cases would be limited with a 
decrease in the power of the test, leading to a less meaningful gene signature. We 
believe that enrolling patients in a prospective trial, as performed in our study, should 
decrease the number of accidental findings related to associated genes. Furthermore, we 
performed an integrated analysis of the two trials, using them as a training set and 
validation set, respectively. 
Our clinicopathological and gene expression analyses for prediction of 
response to chemotherapy and recurrence resulted in two preliminary set of genes 
predictive of pCR and DFS, which may provide guidance regarding individual 
therapeutic decisions. RNA genomic analysis was feasible in 73% of the specimens, 
resulting in successful molecular classification, suggesting that HER2- tumours have a 
higher likelihood of gene clustering. We wish to further expand and validate this 
analysis by using integrated data from larger retrospective populations from previously 
published studies (Madden et al, 2013) or global prospective trials.  
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SUPPLEMENTARY FIGURES 
・  
Supplementary Figure 1  
・ Intrinsic hierarchical clustering of genes and arrays. The top bar shows the response of each 
sample to preoperative chemotherapy, with pCR in blue and non-pCR in white. The lower 
bar shows subtypes differentiated by immunohistochemical staining, with HR+/HER2- in 
white, HR+/HER2+ in orange, HR-/HER2+ in red, and HR-/HER2- in green. Each 
coloured square represents the relative transcript abundance with highest expression in red, 
average expression in yellow, and lowest expression in white. 
・  
Supplementary Figure 2  
・ The 100 top-ranked gene probes predicting pCR were selected by the Wilcoxon test from 
the training set (left panel). We applied those to the validation set (right panel) by support 
vector machine and showed reproducible results in HER2-negative breast cancer. The 
colours of the top bars and the squares correspond to those in Supplementary Figure 1. 
・  
・ Supplementary Figure 3 
・ The discrimination markers predicting pCR were analysed using the training and validation 
sets, and the lowest test error of 7% was observed when the number of markers fitted in the 
model was four, which included HER2-negative status, and the following three genes: 
N-myc and STAT interactor, tryptophanyl-tRNA synthetase, and IQ motif-containing E. 
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